Oncology is one of the most heavily regulated environments in healthcare construction because it combines ionizing radiation (linear accelerators, brachytherapy sealed sources, CT simulators) with hazardous-drug compounding (antineoplastic agents under USP <800>). No single code governs an oncology project; instead a stack of federal regulations, consensus standards, accreditation requirements, and state/local enforcement converge — each authored by a different body, each with a different legal force. This article maps who issues what, what legal weight it carries, and how the documents interlock so a project team can build the correct compliance basis before design begins. It is the orientation layer for the deeper technical Articles in this Chapter (vault shielding physics, USP <800> ventilation, structural/HVAC/power) — those articles execute the requirements this one frames.

The regulatory stack has four distinct layers

It is essential to keep straight that the documents governing an oncology build are not peers. They differ in legal authority and in who enforces them. Confusing a consensus standard (advisory until adopted) with a regulation (legally binding on its own) is a common and expensive error.

The practical rule: a consensus standard becomes law only when an Authority Having Jurisdiction (AHJ) adopts it by reference. NCRP reports and the FGI Guidelines are authoritative engineering documents, but their teeth come from a state or local jurisdiction citing a specific edition in regulation. Always confirm the adopted edition with the AHJ — jurisdictions routinely lag the latest published version.

NCRP defines the radiation-shielding design basis

The National Council on Radiation Protection and Measurements (NCRP) publishes the consensus reports that govern how radiation-therapy and imaging shielding is engineered. NCRP does not enforce anything — it is a congressionally chartered scientific body — but its reports are the universally accepted methodology that qualified medical physicists use, and they are commonly cited (directly or via state radiation-control regulations) as the design basis.

The reports most relevant to an oncology project:

• NCRP Report No. 151 — Structural Shielding Design and Evaluation for Megavoltage X- and Gamma-Ray Radiotherapy Facilities. This is the controlling document for linear-accelerator vault design: primary and secondary barrier calculations, maze/labyrinth modeling, neutron capture-gamma considerations for high-energy beams (typically above ~10 MV), and door/penetration treatment. (The shielding-calculation mechanics themselves are covered in the vault-shielding Article; here the point is that Report 151 is the named basis a project must reference.)
• NCRP Report No. 147 — Structural Shielding Design for Medical X-Ray Imaging Facilities. Governs the CT-simulation room and diagnostic/imaging shielding in the cancer center.
• NCRP Report No. 49 — the legacy radiotherapy-shielding report largely superseded by 151 for new design, but still referenced in some older state regulations; confirm which edition the AHJ adopts.
• NCRP Reports No. 116 / 105 — dose-limit and design-philosophy background (controlled vs. uncontrolled areas, the shielding design goal P, occupancy factors). These set the targets the barrier calculations are designed to meet.

Key consequence for the project: NCRP methodology requires that shielding be designed and signed by a Qualified Medical Physicist (QMP), and that a shielding report be produced and submitted to the radiation-control authority before construction. The physicist's report — not the architect's drawings — is the governing document for barrier thicknesses, and it must be in hand early because vault concrete mass drives the structural and foundation design.

NRC (or the Agreement State) regulates radioactive material — not the accelerator

A critical and frequently misunderstood split:

• Linear accelerators produce radiation electronically (no radioactive source) and are therefore not regulated by the NRC. They fall under state radiation-control programs (often within the state department of health), which license machine-produced-radiation facilities and typically adopt model rules based on the Conference of Radiation Control Program Directors (CRCPD) Suggested State Regulations.
• Brachytherapy and other sealed/unsealed radioactive sources (e.g., HDR afterloader Ir-192 sources, Cs-137, I-125/Pd-103 seeds, radiopharmaceuticals) are regulated under the federal Nuclear Regulatory Commission (NRC) framework — primarily 10 CFR Part 20 (radiation protection standards) and 10 CFR Part 35 (medical use of byproduct material).

In Agreement States (the majority of US states), the NRC has relinquished day-to-day regulatory authority to the state, which administers a program at least as stringent as the federal rules. So a project may answer to: the state for the linac, the state radioactive-material program (acting under the NRC Agreement) for brachytherapy, and occasionally the NRC directly in the handful of non-Agreement States. The licensing pathway differs accordingly and must be identified at project kickoff because it dictates submittal content, source-security construction requirements, and the radiation-safety program structure.

Construction-relevant requirements flowing from Part 20/Part 35 include source storage and security (afterloader vault, source safes), interlocked treatment-room entrances, area monitoring, and posted controlled-area boundaries — all of which become physical design constraints (the radiation-safety and licensing Article covers the program and survey side).

USP <797>, <800> and <825> govern the pharmacy and compounding spaces